Key result
Biomarkers such as natriuretic peptides, MR-proANP, MR-proADM, sST2, copeptin, and Gal-3 provide valuable non-invasive diagnostic and prognostic information in acute heart failure syndromes.
Why the study?
Clinical data lacks sensitivity and specificity in heart failure diagnosis, and literature lacks comprehensive guidance on biomarker utilization in acute heart failure syndrome.
This review summarizes the utility of laboratory biomarkers, particularly natriuretic peptides, in the diagnosis, prognosis, and management of acute heart failure syndromes.
Answers are grounded in this paper and cite their sources.
May inform acute HF prognosis; hypothesis-generating and requires prospective validation before practice change.
Heart failure is one of the leading healthcare problems in the world. Clinical data lacks sensitivity and specificity in the diagnosis of heart failure. Laboratory biomarkers are a non-invasive method of assessing suspected decompensated heart failure. Biomarkers such as natriuretic peptides have shown promising results in the management of heart failure. The literature does not provide comprehensive guidance in the utilization of biomarkers in the setting of acute heart failure syndrome. Many conditions that manifest with similar pathophysiology as acute heart failure syndrome may demonstrate positive biomarkers. The following is a review of biomarkers in heart failure, enlightening their role in diagnosis, prognosis and management of heart failure.
No takes yet. Share an insight, caveat, or question.
Al‐Sadawi et al. (2021) conducted a review in Acute Heart Failure Syndromes. Cardiac Biomarkers was evaluated. Biomarkers such as natriuretic peptides, MR-proANP, MR-proADM, sST2, copeptin, and Gal-3 provide valuable non-invasive diagnostic and prognostic information in acute heart failure syndromes.
Synapse has enriched 10 related papers. Consider them for comparative context: